PETHEMA Foundation: Leukemia, Lymphoid trials
The registry lists 16 Leukemia, Lymphoid studies with PETHEMA Foundation as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 3Phase 3 2Phase 4 8No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Treatment Protocol for Newky Diagnosed Adult Ph Positive ALLNot yet recruitingNCT06175702
- Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaCompletedNCT04178798Phase 3
- REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT03742323Phase 1/2
- Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With OfatumumabStatus unknownNCT03280160Phase 2
- Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTSCompletedNCT01540812
- Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVEStatus unknownNCT01491763Phase 4
- Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 YearsStatus unknownNCT01376427Not applicable
- Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)Status unknownNCT01366898Phase 4
- PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 YearsStatus unknownNCT01358201Phase 4
- PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic LeukemiaTerminatedNCT00944008Phase 3
- Treatment of High Risk Adult Acute Lymphoblastic LeukemiaCompletedNCT00853008Phase 4
- LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic LeukemiaCompletedNCT00526409Phase 4
- LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia PositiveCompletedNCT00526305Phase 4
- LAL-BR/2001: Study Treatment to Low Risk ALLCompletedNCT00526175Phase 4
- PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaCompletedNCT00494897Phase 4
- Glivec in Ph Positive Lymphoblastic LeukemiaCompletedNCT00388895Phase 2